Logo

Bayer Reports Results of Xarelto (rivaroxaban) in P-III EINSTEIN-Jr. Study for Venous Thromboembolism

Share this

Bayer Reports Results of Xarelto (rivaroxaban) in P-III EINSTEIN-Jr. Study for Venous Thromboembolism

Shots:

  • The P-III EINSTEIN-Jr. study involves assessing of Xarelto (20mg) vs SOC (heparins as monothx. or in combination with Vit.K antagonist like warfarin) in 500 children in ratio (2:1) with acute VTE who had started heparin therapy aged ≤ 17yrs.
  • The P-III EINSTEIN-Jr. study results: VTE reoccurrence (1.2% vs 3.0%); improvement in thrombotic burden; bleeding episode [3% (all non-major bleeds) vs 1.9% (2 major & 1 non-major)]; safety profile is consistent to prior studies in adults
  • Xarelto is a non-vitamin K antagonist oral anticoagulant (NOAC) and is approved for eight indications- jointly developed by Bayer & Janssen. Bayer plans to submit MAA to EMA for extension of the Xarelto- making it available for children with VTE

Click here to read full press release/ article | Ref: Bayer | Image: Yahoo Finance


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions